Literature DB >> 9235396

[Keratoacanthoma of the eyelid area. Problems and risks in diagnosis and therapy].

C R Hintschich1, F H Stefani.   

Abstract

BACKGROUND: Keratoacanthoma of the eyelid is a benign skin lesion. Because it regresses spontaneously observation without surgical intervention is the generally accepted method of management. This concept, which was developed in the sixties, is questioned on the basis of personal experience and a review of the literature. Recommendations for a rational management of the disease are suggested.
METHOD: Two patients with clinically diagnosed eyelid keratoacanthomas are reported with their complicated disease course. A review of the dermatological and ophthalmic literature is presented.
CONCLUSIONS: For the correct diagnosis a sufficiently large and representative histological specimen is mandatory. The difficulty of differentiating between keratoacanthoma and squamous cell carcinoma is stressed. Surgery of advanced eyelid lesions is so much more destructive that early simple excision is advocated rather than a policy of initial observation.

Entities:  

Mesh:

Year:  1997        PMID: 9235396     DOI: 10.1055/s-2008-1035045

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  4 in total

1.  [Differential eyelid tumor diagnosis. I].

Authors:  L Holbach; C Cursiefen; A Jünemann; A Viestenz; A Nasr
Journal:  Ophthalmologe       Date:  2002-05       Impact factor: 1.059

2.  [Bilateral ulcerating lid tumors with atopic conjunctivitis].

Authors:  H Mittelviefhaus; C Auw-Hädrich; H Witschel
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

3.  [Rapidly growing tumor of the eyebrow].

Authors:  U B Kottler; A Bergua
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

Review 4.  [Therapy options for malignant eyelid tumors].

Authors:  M Weiling; A Bergua; F E Kruse; L Holbach
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.